Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Ferric Maltol in Pediatric Iron Deficiency
NCT03181451Phase 1Completed
- Sponsor
- Shield Therapeutics plc
- Start
- Mar 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ferric maltol in iron deficiency anemia (IDA) (3 arms), sponsored by Shield Therapeutics plc. Primary endpoints: Maximum Plasma Concentration of Maltol Glucuronide at Day 10, Area Under The Curve of Maltol Glucuronide at Day 10 and 10 more. Started Mar 2017; status: completed.
02
Drugs
ferric maltol
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT03181451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03181451.